Reamberin

DRUG3 trials

Sponsors

POLYSAN Scientific & Technological Pharmaceutical Company

Conditions

COVID-19Diabetic KetoacidosisEthanol Intoxication

Phase 2

REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis

RecruitingNCT06955416

POLYSAN Scientific & Technological Pharmaceutical CompanyDiabetic Ketoacidosis

Start: 2025-05-01End: 2027-12-31Target: 312Updated: 2025-06-24

Unknown Phase

Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

CompletedNCT05172180

POLYSAN Scientific & Technological Pharmaceutical CompanyCOVID-19

Start: 2020-12-01End: 2021-04-01Updated: 2024-12-19

Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication

CompletedNCT05715723

POLYSAN Scientific & Technological Pharmaceutical CompanyEthanol Intoxication

Start: 2022-09-15End: 2025-02-28Updated: 2025-04-18